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Metformin and Myocardial Injury in Patients With Diabetes and
ST-Segment Elevation Myocardial Infarction: A Propensity Score
Matched Analysis
Suresh Basnet, MD; Andrzej Kozikowski, PhD; Amgad N. Makaryus, MD; Renee Pekmezaris, PhD; Roman Zeltser, MD;
Meredith Akerman, MS; Martin Lesser, PhD; Gisele Wolf-Klein, MD
Background-—Although animal studies have documented metformin’s cardioprotective effects, the impact in humans remains
elusive. The study objective was to explore the association between metformin and myocardial infarct size in patients with diabetes
presenting with ST-segment elevation myocardial infarction.
Methods and Results-—Data extraction used the National Cardiovascular Data CathPCI Registry in all patients with diabetes aged
>18 years presenting with ST-segment elevation myocardial infarction at 2 academic medical centers from January 2010 to
December 2013. The exposure of interest was ongoing metformin use before the event. Propensity score matching was used for
the metformin and nonmetformin groups on key prognostic variables. All matched pairs had acceptable D scores of <10%,
conﬁrming an efﬁcient matching procedure. The primary outcome was myocardial infarct size, reﬂected by peak serum creatine
kinase–myocardial band, troponin T, and hospital discharge left ventricular ejection fraction. Of all 1726 ST-segment elevation
myocardial infarction cases reviewed, 493 patients had diabetes (28.5%), with 208 metformin users (42.1%) and 285 nonusers.
Matched pairs analysis yielded 137 cases per group. The difference between metformin and nonmetformin groups was 18.1 ng/
mL (95% CI 55.0 to 18.8; P=0.56) for total peak serum creatine kinase–myocardial band and 1.1 ng/mL (95% CI 2.8 to 0.5;
P=0.41) for troponin T. Median discharge left ventricular ejection fraction in both groups was 45, and the difference between
metformin and nonmetformin users was 0.7% (95% CI 2.2 to 3.6; P=0.99).
Conclusions-—No statistically signiﬁcant association of cardioprotection was found between metformin and myocardial infarct size
in patients with diabetes and acute ST-segment elevation myocardial infarction. ( J Am Heart Assoc. 2015;4:e002314 doi:
10.1161/JAHA.115.002314)
Key Words: metformin • myocardial injury • ST-segment elevation myocardial infarction
T he American Heart Association considers diabetes to bea “major controllable risk factor for cardiovascular
disease [CVD].”1 In addition to lifestyle changes, pharmaco-
logical therapeutic options including oral hypoglycemic agents
are being actively investigated to determine their potential
impact on CVD-related death independent of their glucose-
lowering effects. To date, only metformin has shown promis-
ing results.2–6
Metformin is associated with lower mortality, both total and
cardiovascular.7 Metformin seems to reduce myocardial
ischemia–reperfusion injury in animal studies8 and in humans
based on a few preliminary studies9,10; however, there is
controversy regarding the possible cardioprotective effect of
metformin. Few recent studies have speciﬁcally investigated
the relationship between metformin use and myocardial
infarction (MI). In a 2013 retrospective analysis, Zhao et al
found that chronic pretreatment with metformin was associ-
ated with the reduction of the no-reﬂow phenomenon in
patients with diabetes mellitus after primary angioplasty for
acute MI.9 In a 2014 retrospective cohort study, Lexis et al
sought to investigate the association between metformin use
and MI size in patients presenting with an acute MI.10 The
researchers found that the use of metformin treatment was an
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independent predictor of smaller MI size.10 Nevertheless,
Abualsuod et al found in a chart review study that the use of
metformin in patients with diabetes was not associated with
improvements in left ventricular ejection fraction (LVEF)
despite being related to both 30-day and 12-month all-cause
mortality.11 This ﬁnding suggests that metformin may be
beneﬁcial without directly inﬂuencing LVEF. In a prospective
trial of metformin for ST-segment elevation MI (STEMI) in
nondiabetic patients, Lexis et al also failed to show a beneﬁcial
effect of metformin on LVEF after 4-month follow-up.12
Despite the encouraging ﬁndings showing that metformin
use is associated with a lower risk of CVD-related mortality,
only a few studies with human participants have speciﬁcally
investigated the relationship between metformin use and
myocardial infarct size.9–11,13,14 We sought to use propensity
score analysis to investigate the association between met-
formin use and infarct size prior to percutaneous coronary
intervention (PCI) in patients with diabetes presenting with
STEMI.
Methods
Data Source
A retrospective cohort study of patients with diabetes (types 1
and 2) presenting with STEMI was conducted at 2 large
tertiary academic medical centers in the New York metropoli-
tan area. After institutional review board approval (14-122A),
data were extracted from the American College of Cardiology
National Cardiovascular Data Registry (NCDR) covering the
period from January 1, 2010, through December 31, 2013.
The NCDR was developed in 1997 to capture reliable clinical,
process-of-care, and outcomes data for patients undergoing
coronary angiography and PCI in the United States, enabling
practitioners to explore strategies for improving cardiovascu-
lar care.15,16 The registry contains >250 data ﬁelds including
patient medical history, risk factors, demographics, hospital
presentation, initial cardiac status, procedural description,
laboratory results, medication regimens, and in-hospital
outcomes.15 The registry contains 12 million records from
1577 institutions in the United States from 1998 to the
present.15 Prior to propensity score matching (PSM), there
were 208 metformin and 285 nonmetformin patients who met
the eligibility criteria for this study. The ﬁnal sample size after
PSM was 274 participants (137 metformin and 137 non-
metformin patients).
Study Population and Selection Criteria
All patients were aged ≥18 years with known diabetes
(deﬁned by a history of diabetes diagnosed by a physician
or fasting blood glucose >7 mmol/L or 126 mg/dL, regard-
less of duration of disease or need for glucose-lowering
medications) and presented with STEMI or STEMI equivalent
(characterized by the presence of both electrocardiogram
evidence and cardiac biomarker criteria). Data for all patients
in this study were extracted from the NCDR CathPCI Registry
version 4.4. Data on use of metformin, antiplatelet agents,
and statin therapy prior to hospitalization were extracted by
manual review of electronic health records for each patient.
Exposure of Interest
The exposure of interest was metformin use prior to STEMI.
Metformin therapy prior to STEMI was deﬁned as the
documentation of a prescription for metformin at a dose of
≥250 mg per day that was in effect on the day prior to
admission, as obtained from patients’ electronic home
medication reconciliation order sheets.
Variables
Preprocedure cardiac biomarkers were recorded, including
creatine kinase–myocardial band (CKMB) and troponin T
measurements. These laboratory tests were drawn at our
facilities and excluded point-of-care or bedside testing, with
the target value being the last value between arrival and
current procedure prior to PCI. Discharge LVEF (DCLVEF) after
PCI was collected as well as postprocedure CKMB and
troponin T peak values (within the interval of 6 to 24 hours
after PCI with the target value being the highest value
between 6 and 24 hours after the current procedure). Other
variables collected included sex, body mass index, race,
history of smoking, hypertension, dyslipidemia, prior MI, use
of antianginal medications, antiplatelet agents, statin therapy,
family history of coronary artery disease, prior PCI, prior heart
failure, coronary artery bypass grafting, CVD, peripheral
arterial disease, chronic lung disease, left ventricular systolic
dysfunction, time from symptom onset to PCI (in hours),
cardiogenic shock at presentation, and current anterior
infarct.
Propensity Score Matching
Given that this was a retrospective cohort study and not a
randomized trial, it was necessary to achieve comparability of
the metformin (intervention) and nonmetformin (control)
groups with regard to potential confounding variables. This
was accomplished using PSM (Figure).17 The following
variables, chosen from the CathPCI Registry, were used to
compute the propensity score for each patient: sex, race,
smoking history, hypertension, dyslipidemia, prior MI, antiang-
inal medication, antiplatelets, statin, family history of coronary
artery disease, prior PCI, body mass index, time from
DOI: 10.1161/JAHA.115.002314 Journal of the American Heart Association 2
Metformin and Myocardial Injury in STEMI Basnet et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
symptom onset to PCI (in hours), and anterior infarct. In
addition, a composite predictor variable was used that
indicated the presence of at least 1 of the following
conditions: prior heart failure, coronary artery bypass grafting,
prior CVD, prior peripheral arterial disease, chronic lung
disease, left ventricular systolic dysfunction, and cardiogenic
shock. PSM was accomplished using the SAS macro
OneToManyMTCH.18
The standardized difference statistic (D, expressed as a
percentage) was used to evaluate comparability of the 2
groups on each confounding variable before and after PSM.19
Comparability of the 2 groups with respect to the potential
confounders before matching (n=208 metformin, n=285
controls) and after matching (n=137 metformin, n=137
controls) was also evaluated using descriptive statistics; the
2-sample t test for continuous variables; and the chi-square
test or Fisher exact test, as deemed appropriate, for
categorical variables. Summary statistics before matching
(Table 1) and after matching (Table 2) were reported as
frequency (percentage) for categorical data and as mean and
SD and median (25th, 75th percentiles) for continuous data.
It should be noted that it is common for the sample size
prior to PSM to be quite large compared with the resulting
sample size after creating matched pairs. This is also the case
in most epidemiological studies in which variable-speciﬁc
matching is used.
Figure. Propensity score matching ﬂow diagram. NCDR indi-
cates National Cardiovascular Data Registry; STEMI, ST-segment
elevation myocardial infarction.
Table 1. Comparability of the Groups Before Matching
Variable
Nonmetformin
(n=285)
Metformin
(n=208) P Value D
Sex (male) 196 (68.8%) 147 (70.7%) 0.651 4.1
Race (white) 132 (46.3%) 88 (42.3%) 0.377 8.1
Smoker 53 (18.6%) 51 (24.5%) 0.111 14.4
Hypertension 246 (86.3%) 174 (83.7%) 0.411 7.4
Dyslipidemia 205 (71.9%) 159 (76.4%) 0.260 10.3
Prior MI 48 (16.8%) 21 (10.1%) 0.033 19.8
Antianginal
medication
152 (53.3%) 90 (43.3%) 0.027 20.2
Antiplatelets 131 (46.0%) 83 (39.9%) 0.180 12.2
Statin 133 (46.7%) 127 (61.1%) 0.002 29.1
Family history of
CAD
29 (10.2%) 23 (11.1%) 0.752 2.9
Prior PCI 58 (20.4%) 37 (17.8%) 0.465 6.7
BMI* 29.36.0
[median
28.4 (25.1,
32.6)]
30.37.5
[median
28.3 (25.8,
32.4)]
0.424 14.2
Time from
symptom onset
to PCI, hours*
9.614.1
[median 4.1
(2.6, 10.2)]
8.112.4
[median
3.8 (2.3,
7.9)]
0.231 11.1
Anterior infarct 99 (35.1%) 60 (30.3%) 0.271 10.2
Combined
predictor
variable†
93 (32.6%) 33 (15.9%) <0.0001 39.8
Prior HF 29 (10.2%) 9 (4.3%) 0.016 —
Prior CABG 19 (6.7%) 6 (2.9%) 0.059 —
Prior CVD 20 (7.0%) 11 (5.3%) 0.435 —
Prior PAD 21 (7.4%) 7 (3.4%) 0.059 —
Chronic lung
disease
12 (4.2%) 5 (2.4%) 0.278 —
Cardio LVSD 14 (4.9%) 6 (2.9%) 0.260 —
Cardiogenic
shock
16 (5.6%) 1 (0.5%) 0.002 —
BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; CVD, cardiovascular disease; HF, heart failure; LVSD, left ventricular
systolic dysfunction; MI, myocardial infarction; PAD, peripheral arterial disease; PCI,
percutaneous coronary intervention.
*All categorical data are reported as frequency (percentage). The 2 continuous variables,
BMI and time from symptom onset to PCI, are reported as meanSD and median (25th,
75th percentiles).
†Only the combined predictor variable was used in propensity score matching. The 7
components of this variable are shown for informational purposes only.
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Primary Outcome
The primary study outcome variable was myocardial infarct
size as demonstrated by the peak levels of cardiac biomarkers
and DCLVEF after the STEMI event. In cases in which CKMB
(and similarly for troponin T) was measured both before and
after the PCI, the larger of the 2 measurements was used to
capture the worst possible cardiac tissue injury. Peak levels of
cardiac biomarkers (CKMB and troponin T) and LVEF after
acute MI have been shown to have a strong correlation with
myocardial infarct size and scar tissue in humans.20,21
Statistical Analyses
Comparisons of the metformin and control groups were
carried out using methods for paired continuous data. For
CKMB and troponin T, the difference between metformin and
control was calculated as the arithmetic difference (metformin
minus control). The paired arithmetic difference was normally
distributed and was analyzed using the paired t test and
associated 95% CIs.
Conﬁdence intervals for the metformin-minus-control
arithmetic difference are presented in the usual way (Table 3).
A result was considered statistically signiﬁcant at the P<0.05
level. All analyses were performed using SAS version 9.3 (SAS
Institute Inc).
Results
Of the 15 individual and composite predictor confounding
variables, 10 had poor standardized difference scores (ie,
>10%) prior to PSM. After PSM, there were 137 pairs of
metformin and control patients. All 15 confounding variables
had acceptable D scores (ie, <10%), indicating that the
matching procedure was efﬁcient in creating balance between
the 2 groups. Tables 1 and 2 show the comparability statistics
before and after PSM, respectively, for each of the potential
confounding variables.
Although the analysis based on PSM is the focus of this
study, it may be of interest to note that a direct, unadjusted,
unmatched comparison of the 208 metformin patients and
285 controls resulted in no signiﬁcant differences with
respect to CKMB, troponin T, or DCLVEF.
Of all 1726 STEMI cases reviewed, 493 patients had
diabetes (28.5%), with 208 (42.1%) metformin users and 285
nonusers. Matched pairs analysis yielded 137 cases per
group. The arithmetic difference between the metformin and
nonmetformin groups was 18.1 ng/mL (95% CI 55.0 to
18.8; P=0.56) for total peak serum CKMB and 1.1 ng/mL
(95% CI 2.8 to 0.5; P=0.41) for troponin T. Median DCLVEF
in both groups was 45. The arithmetic difference of DCLVEF
between metformin and nonmetformin users was 0.7% (95%
CI 2.2 to 3.6; P=0.98).The matched pairs comparison of the
137 metformin and control patients showed no signiﬁcant
differences with respect to CKMB, troponin T, or DCLVEF
(Table 3), with P values ranging from 0.410 to 0.987. The
conﬁdence interval for DCLVEF is narrow, allowing the
Table 2. Comparability of the Groups After Matching
Variable
Nonmetformin
(n=137)
Metformin
(n=137) P Value D
Sex (male) 87 (63.5%) 89 (65.0%) 0.801 3
Race (white) 62 (45.3%) 64 (46.7%) 0.808 2.9
Smoker 27 (19.7%) 30 (21.9%) 0.655 5.4
Hypertension 117 (85.4%) 112 (81.8%) 0.415 9.8
Dyslipidemia 102 (74.5%) 97 (70.8%) 0.498 8.2
Prior MI 22 (16.1%) 18 (13.1%) 0.494 8.2
Antianginal
medication
61 (44.5%) 62 (45.3%) 0.903 1.5
Antiplatelets 62 (45.3%) 62 (45.3%) 1.000 0
Statin 71 (51.8%) 71 (51.8%) 1.000 0
Family history of CAD 12 (8.8%) 15 (11.0%) 0.543 7.3
Prior PCI 28 (20.4%) 30 (21.9%) 0.767 3.6
BMI* 30.46.4
[median
29.2 (25.8,
33.3)]
30.27.1
[median
28.2 (25.8,
32.4)]
0.407 2.9
Time from symptom
onset to PCI, hours*
1.61.1
[median 1.4
(0.9, 2.3)]
1.51.0
[median
1.4 (0.8,
2.1)]
0.570 2.2
Anterior infarct 48 (35.0%) 44 (32.1%) 0.609 6.2
Combined predictor
variable†
20 (14.6%) 20 (14.6%) 1.000 0
Prior HF 4 (2.9%) 7 (5.1%) 0.356 —
Prior CABG 4 (2.9%) 2 (1.5%) 0.684‡ —
Prior CVD 2 (1.5%) 9 (6.6%) 0.031 —
Prior PAD 3 (2.2%) 4 (2.9%) 1.000‡ —
Chronic lung
disease
5 (3.7%) 4 (2.9%) 1.000‡ —
Cardio LVSD 4 (2.9%) 5 (3.7%) 1.000‡ —
Cardiogenic shock 4 (2.9%) 0 (0.0%) 0.122‡ —
BMI indicates body mass index; CABG, coronary artery bypass grafting; CAD, coronary
artery disease; CVD, cardiovascular disease; HF, heart failure; LVSD, left ventricular
systolic dysfunction; MI, myocardial infarction; PAD, peripheral arterial disease; PCI,
percutaneous coronary intervention.
*All categorical data are reported as frequency (percentage). The 2 continuous variables,
BMI and time from symptom onset to PCI, are reported as meanSD and median (25th,
75th percentiles).
†Only the combined predictor variable was used in propensity score matching. The 7
components of this variable are shown for informational purposes only.
‡Fisher exact test.
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conclusion that there is no appreciable difference in this
outcome between the 2 groups.
Discussion
The major objective of our study was to investigate the
association between metformin use prior to PCI and myocar-
dial injury in patients with diabetes and STEMI. In our
propensity score matched study, the results showed no
signiﬁcant differences with respect to CKMB, troponin T, and
DCLVEF.
Numerous studies have shown that metformin is associ-
ated with a lower risk for CVD-related complications and
death.7,13,22–25 In 1998, a study on the effects of intensive
blood glucose control with metformin on macrovascular and
microvascular complications and mortality in overweight
patients with diabetes found that those receiving metformin
had risk reduction of 36% for all-cause mortality and 46% for
diabetes-related death.7 Similarly, in 2002, Johnson et al
documented that metformin therapy was associated with
lower all-cause and cardiovascular mortality compared with
sulfonylurea monotherapy.22 In a 2008 systematic review,
based on 40 controlled trials, Selvin et al found that
metformin treatment was associated with a lower cardiovas-
cular mortality risk compared with other oral glucose-lowering
medications or a placebo.23
In a post hoc analysis from the Diabetes Mellitus Insulin–
Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2
trial, Melbin et al found that metformin was associated with a
lower mortality rate.13 In 2011, a nationwide Danish study
explored the relationship between mortality and cardiovascu-
lar risk associated with different insulin secretagogues
compared with metformin in patients with type 2 diabetes
with or without a previous MI.24 Monotherapy with metformin
resulted in decreased mortality risk compared with glimepir-
ide, glibenclamide, glipizide, and tolbutamide. In a randomized
double-blind placebo-controlled trial investigating the effect of
metformin compared with glipizide on cardiovascular out-
comes in patients with type 2 diabetes and CVD, metformin
treatment led to a signiﬁcantly lower number of major
cardiovascular events compared with glipizide at 5 years (7
versus 14 deaths, respectively).25 The GLP-1 receptor agonist
exenatide has been demonstrated to be cardioprotective in
both animal studies26 and clinical trials.27–29 Conversely,
sulphonylurea antidiabetic drugs seem to disrupt cardiopro-
tection through inhibition of ATP-dependent potassium chan-
nels.30
Animal studies suggest that metformin induces cardiopro-
tection against ischemia and reperfusion injury, independently
from its glucose-lowering effect, by limiting myocardial infarct
size and remodeling.8,31–33 In a 2008 study conducted in rats,
a single metformin dose protected the myocardium against
experimentally induced ischemia 24 hours after administra-
tion of the drug, with an acute increase in myocardial
adenosine monophosphate–activated protein kinase activity
and a signiﬁcant reduction of myocardial infarct size.31 More
recently, in a 2013 study, chronic metformin administration
once again resulted in cardioprotection against infarction in
the form of myocardial resistance to ischemia–reperfusion
injury in diabetic and nondiabetic rats.32 This research
suggests that metformin positively affects mitochondrial
structure through adenosine monophosphate–activated pro-
tein kinase activation and proliferator-activated receptor-c
coactivator (PGC-1a) by restricting the occurrence of myocar-
dial injury from cardiovascular events.
In humans, a recent retrospective cohort study sought to
investigate the association between metformin use and MI
size in patients presenting with an acute MI.10 The
researchers divided patients with diabetes into metformin
versus nonmetformin groups and estimated MI size using
peak values of serum creatine kinase, CKMB, and troponin
T.10 After adjustment for age, sex, Thrombolysis in Myocardial
Infarction ﬂow after PCI, and previous MI, Lexis et al found
that the use of metformin treatment remained an independent
predictor of smaller MI size10; however, in a double-blind,
placebo-controlled study in nondiabetic participants, also
conducted by Lexis et al, the use of metformin compared with
placebo did not result in improved LVEF after 4 months.12 The
negative outcome results shown by Lexis et al in their trial
could have been due to the study procedure, which involved
providing patients with metformin after the event of STEMI
and PCI.
Table 3. Matched Pairs Analyses of Primary Outcome Variables
Metformin Nonmetformin Difference* and 95% CI for Difference P Value
CKMB (n=136 pairs) 149.6129.0 (median 99.0) 167.6180.7 (median 92.6) 18.1 (55.0 to 18.8) 0.561
Troponin T (n=135 pairs) 5.74.9 (median 3.9) 6.89.4 (median 4.1) 1.1 (2.8 to 0.5) 0.410
DCLVEF (n=127 pairs) 43.511.1 (median 45.0) 42.811.6 (median 45.0) 0.7 (2.2 to 3.6) 0.987
Data were analyzed using the paired t test. CKMB indicates creatine kinase–myocardial band; DCLVEF, discharge left ventricular ejection fraction.
*A positive (negative) difference indicates a larger (smaller) value for the metformin group.
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Our study was speciﬁcally designed to investigate the
association of metformin and myocardial infarct size in
patients with diabetes on metformin therapy prior to the
event. We used PSM to control for 15 potential confounding/
composite variables including sex, race, smoking history,
hypertension, dyslipidemia, prior MI, antianginal medication,
antiplatelets, statin, family history of coronary artery disease,
prior PCI, body mass index, time from symptom onset to PCI,
anterior infarct, and a combined predictor variable (prior heart
failure, coronary artery bypass grafting, CVD, peripheral
arterial disease, chronic lung disease, cardiovascular left
ventricular systolic dysfunction, and cardiogenic shock).
The “negative” results in our study need to be interpreted
in the context of whether these might be type II errors. A way
to address this is by examining the associated conﬁdence
intervals as follows: Given the narrow conﬁdence interval for
DCLVEF (95% CI 2.2 to 3.6; P=0.987) and even at the
extremes of this conﬁdence interval, there appears to be no
clinically signiﬁcant difference, which allows us to conclude
that there is no appreciable difference in DCLVEF between the
metformin and nonmetformin groups. The same can be said of
troponin T because its conﬁdence interval (95% CI 2.8 to
0.5; P=0.41) also suggests that, at the extremes, there is no
clinically appreciable difference.
With regard to difference in CKMB, the wider conﬁdence
interval and the lower and upper end points (95% CI 55.0 to
18.8) suggest that group differences could be clinically
meaningful. Consequently, the observed lack of group differ-
ence for CKMB may be inconclusive (ie, type II error).
The main limitation of this study is that it takes into
account only ﬁnal infarct size, not the myocardial salvage
area. We found that the infarct size was similar in both
groups, but there are 2 confounding factors with this result:
variations in coronary anatomy and the possibility that
coronary occlusions were more proximal in 1 group than in
the other group, so the area at risk (the ischemic area) was
larger, and that justiﬁes a larger infarct size. We cannot rule
out that metformin was cardioprotective, but the metformin
group had a larger ischemic area from the very beginning.
Another limitation of our study is that we did not collect data
on the duration of metformin use, the speciﬁc doses, or
patients’ adherence to their medication regimens. If patients
started metformin the previous day, they would still be
achieving plasma steady-state levels; however, not knowing
the speciﬁc dose (metformin may be cardioprotective at
speciﬁc doses) and whether they were noncompliant with the
treatment limits our study results. An additional limitation is
that we could not differentiate between patients with type 1
and 2 diabetes in our sample because the CathPCI Registry
groups all patients with diabetes into 1 category; however,
metformin is the ﬁrst-line drug for type 2 diabetes and
typically is not prescribed to patients with type 1 diabetes,
who usually are insulin dependent. A last limitation of our
study is that we could use data from only 2 of our institutions.
NCDR compiles data from 1577 participating institutions but
provides access to raw data for research only to the
institution from which the data originated. Data from other
institutions are provided in the form of national risk-adjusted
benchmark reports. In addition, NCDR does not provide data
on use of metformin; in our study, this was extracted from
manual review of individual patients’ electronic medical
records.
Although studies have previously documented beneﬁcial
cardioprotective effects of metformin, the exact mechanism
and presence of this effect in humans remains elusive. It
appears that infarct size in the setting of myocardial injury is
not associated with metformin use in the present era of
primary PCI. Further prospective controlled trials may help
elucidate the effect of metformin with respect to cardiopro-
tection and allow for the enhanced care of patients experi-
encing an acute coronary event.
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